APPRAISE-2 Study With Investigational Compound Apixaban In Acute Coronary Syndrome Discontinued

Links shared publicly online about this topic.

  • 714
    total visits

APPRAISE-2 Study With Investigational Compound Apixaban In Acute Coronary Syndrome Discontinued

medicalnewstoday.com —

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syn

View full resource at medicalnewstoday.com

Tags: Disease and Condition, Clinical Trial, Pfizer, Bristol-Myers Squibb, Estrogen, Scientist, Science

  • Share

Most Recently Shared on November 20, 2010 at 10:05 am By:

mnt_cardiovasc MNT Cardiovascular

APPRAISE-2 Study With Investigational Compound Apixaban In Acute Coronary Syndrome Discontinued http://mnt.to/3MTp #cardiovascular

1 year ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Heart News MNT Heart News

MNT Clinical Trials MNT Clinical Trials

Heart Disease OW Heart Disease OW

APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued - Drugs.com MedNews

drugs.com — “Nov 18, 2010 - Bristol-Myers Squibb Company (NYSE BMY) and Pfizer (NYSE PFE) today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical” View full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on November 19, 2010 at 3:08 pm By:

Drugs_Devices Drugs and Devices OW OW Health

APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued: PRINCETON... http://bit.ly/94rWRc #drug

1 year ago...

Reply

Retweet

Favorite

Advertisement